ECSP16082599A - Quinazolin-thf-aminas halogenadas como inhibidores de pde1 - Google Patents
Quinazolin-thf-aminas halogenadas como inhibidores de pde1Info
- Publication number
- ECSP16082599A ECSP16082599A ECIEPI201682599A ECPI201682599A ECSP16082599A EC SP16082599 A ECSP16082599 A EC SP16082599A EC IEPI201682599 A ECIEPI201682599 A EC IEPI201682599A EC PI201682599 A ECPI201682599 A EC PI201682599A EC SP16082599 A ECSP16082599 A EC SP16082599A
- Authority
- EC
- Ecuador
- Prior art keywords
- quinazolin
- thf
- pde1 inhibitors
- halogenated amines
- halogenated
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title abstract 2
- 150000001412 amines Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona quinazolin-THF-aminas halogenadas como inhibidores de PDE1 y su uso como un medicamento, en particular para el tratamiento de trastornos neurodegenerativos y trastornos psiquiátricos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400194 | 2014-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP16082599A true ECSP16082599A (es) | 2017-02-24 |
Family
ID=52779655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201682599A ECSP16082599A (es) | 2014-04-04 | 2016-10-20 | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 |
Country Status (38)
Country | Link |
---|---|
US (2) | US10005764B2 (es) |
EP (1) | EP3126354B1 (es) |
JP (1) | JP6554116B2 (es) |
KR (1) | KR20160138084A (es) |
CN (2) | CN109999039A (es) |
AP (1) | AP2016009521A0 (es) |
AR (1) | AR101155A1 (es) |
AU (1) | AU2015239696B2 (es) |
CA (1) | CA2943011A1 (es) |
CL (1) | CL2016002515A1 (es) |
CR (1) | CR20160463A (es) |
CY (1) | CY1122784T1 (es) |
DK (1) | DK3126354T3 (es) |
DO (1) | DOP2016000263A (es) |
EA (1) | EA032579B1 (es) |
EC (1) | ECSP16082599A (es) |
ES (1) | ES2776359T3 (es) |
GE (1) | GEP20186920B (es) |
GT (1) | GT201600213A (es) |
HR (1) | HRP20200369T1 (es) |
IL (1) | IL248078B (es) |
JO (1) | JO3628B1 (es) |
LT (1) | LT3126354T (es) |
MA (1) | MA39837B1 (es) |
MX (1) | MX364519B (es) |
PE (1) | PE20161380A1 (es) |
PH (1) | PH12016501938A1 (es) |
PL (1) | PL3126354T3 (es) |
PT (1) | PT3126354T (es) |
RS (1) | RS60017B1 (es) |
RU (1) | RU2692808C2 (es) |
SG (1) | SG11201608190YA (es) |
SI (1) | SI3126354T1 (es) |
SV (1) | SV2016005297A (es) |
TW (1) | TWI664178B (es) |
UA (1) | UA119166C2 (es) |
WO (1) | WO2015150254A1 (es) |
ZA (1) | ZA201606566B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109999039A (zh) | 2014-04-04 | 2019-07-12 | H.隆德贝克有限公司 | 作为pde1抑制剂的卤化的喹唑啉-thf-胺 |
US10981916B2 (en) | 2016-12-28 | 2021-04-20 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
DK3717488T3 (da) * | 2017-11-27 | 2021-12-13 | Dart Neuroscience Llc | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |
CN117105809B (zh) * | 2023-10-20 | 2024-05-03 | 中国农业大学 | 一种苯甲酰苯胺化合物及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10042058A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
ZA200507979B (en) * | 2003-03-03 | 2007-03-28 | Vertex Pharma Inc | Quinazolines useful as modulators of ion channels |
GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
CA2641670A1 (en) * | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
US20070265258A1 (en) * | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
JP2013505909A (ja) * | 2009-09-24 | 2013-02-21 | ビーエーエスエフ ソシエタス・ヨーロピア | 無脊椎動物害虫を駆除するためのアミノキナゾリン化合物 |
US20130116241A1 (en) * | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
TW201609713A (zh) * | 2013-12-19 | 2016-03-16 | H 朗德貝克公司 | 作爲pde1抑制劑之喹唑啉-thf-胺 |
TW201611834A (en) | 2014-02-07 | 2016-04-01 | Lundbeck & Co As H | Hexahydrofuropyrroles as PDE1 inhibitors |
AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
EA030032B1 (ru) | 2014-04-04 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов |
LT3126330T (lt) | 2014-04-04 | 2019-04-25 | Pfizer Inc. | Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių |
CN109999039A (zh) | 2014-04-04 | 2019-07-12 | H.隆德贝克有限公司 | 作为pde1抑制剂的卤化的喹唑啉-thf-胺 |
AR099936A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
MA39843A (fr) | 2014-04-04 | 2017-02-08 | Hoffmann La Roche | Pyridine-2-amides utiles comme agonistes de cb2 |
-
2015
- 2015-03-27 CN CN201910110735.2A patent/CN109999039A/zh active Pending
- 2015-03-27 MX MX2016012955A patent/MX364519B/es active IP Right Grant
- 2015-03-27 LT LTEP15713186.3T patent/LT3126354T/lt unknown
- 2015-03-27 KR KR1020167027262A patent/KR20160138084A/ko not_active Application Discontinuation
- 2015-03-27 MA MA39837A patent/MA39837B1/fr unknown
- 2015-03-27 DK DK15713186.3T patent/DK3126354T3/da active
- 2015-03-27 AP AP2016009521A patent/AP2016009521A0/en unknown
- 2015-03-27 PE PE2016001906A patent/PE20161380A1/es unknown
- 2015-03-27 EP EP15713186.3A patent/EP3126354B1/en active Active
- 2015-03-27 UA UAA201610191A patent/UA119166C2/uk unknown
- 2015-03-27 SG SG11201608190YA patent/SG11201608190YA/en unknown
- 2015-03-27 CN CN201580017454.2A patent/CN106132953B/zh active Active
- 2015-03-27 ES ES15713186T patent/ES2776359T3/es active Active
- 2015-03-27 EA EA201691773A patent/EA032579B1/ru not_active IP Right Cessation
- 2015-03-27 CA CA2943011A patent/CA2943011A1/en not_active Abandoned
- 2015-03-27 SI SI201531112T patent/SI3126354T1/sl unknown
- 2015-03-27 PT PT157131863T patent/PT3126354T/pt unknown
- 2015-03-27 GE GEAP201514286A patent/GEP20186920B/en unknown
- 2015-03-27 WO PCT/EP2015/056713 patent/WO2015150254A1/en active Application Filing
- 2015-03-27 RS RS20200239A patent/RS60017B1/sr unknown
- 2015-03-27 RU RU2016138743A patent/RU2692808C2/ru active
- 2015-03-27 PL PL15713186T patent/PL3126354T3/pl unknown
- 2015-03-27 CR CR20160463A patent/CR20160463A/es unknown
- 2015-03-27 US US15/301,210 patent/US10005764B2/en active Active
- 2015-03-27 JP JP2016560728A patent/JP6554116B2/ja active Active
- 2015-03-27 AU AU2015239696A patent/AU2015239696B2/en not_active Ceased
- 2015-03-30 JO JOP/2015/0058A patent/JO3628B1/ar active
- 2015-03-31 TW TW104110439A patent/TWI664178B/zh not_active IP Right Cessation
- 2015-04-01 AR ARP150101009A patent/AR101155A1/es unknown
-
2016
- 2016-09-22 ZA ZA2016/06566A patent/ZA201606566B/en unknown
- 2016-09-27 IL IL248078A patent/IL248078B/en active IP Right Grant
- 2016-09-27 DO DO2016000263A patent/DOP2016000263A/es unknown
- 2016-09-29 PH PH12016501938A patent/PH12016501938A1/en unknown
- 2016-10-03 SV SV2016005297A patent/SV2016005297A/es unknown
- 2016-10-03 GT GT201600213A patent/GT201600213A/es unknown
- 2016-10-03 CL CL2016002515A patent/CL2016002515A1/es unknown
- 2016-10-20 EC ECIEPI201682599A patent/ECSP16082599A/es unknown
-
2018
- 2018-06-13 US US16/007,561 patent/US10526319B2/en active Active
-
2020
- 2020-03-04 CY CY20201100196T patent/CY1122784T1/el unknown
- 2020-03-04 HR HRP20200369TT patent/HRP20200369T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
SV2018005801A (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1 | |
BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
ECSP16082599A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 |